A Phase 1, Open-label, Single-dose Study to Assess the Pharmacokinetics (PK) of CC-122 in Subjects With Mild, Moderate and Severe Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Avadomide (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 28 Feb 2018 Status changed from recruiting to completed.
- 05 Apr 2017 Status changed from not yet recruiting to recruiting.
- 03 Apr 2017 New trial record